A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
← catalyst calendarNCT07665879 · readout ≤ 377 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
115estimated
Sites
2
Countries
Germany, Sweden
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-24 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
Interventions
- Drug: Eloralintide — also filed as LY3841136
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFChange From Baseline In Hyperinsulinemic Euglycemic Clamp (HEC) Predicted Clamp-Derived Insulin Sensitivity (M-value)
measured Baseline, Week 24
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed